Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8956319 | Molecular and Cellular Endocrinology | 2018 | 29 Pages |
Abstract
CART expression was found in glucose-dependent insulinotropic polypeptide (GIP)-producing K-cells and glucagon-like peptide-1 (GLP-1)-producing L-cells in human duodenum and jejunum and circulating CART levels were increased 60â¯min after a meal in humans. CART expression was increased by fatty acids and GIP, but unaffected by glucose in GLUTag and STC-1â¯cells. Exogenous CART had no effect on GIP and GLP-1 expression and secretion in GLUTag or STC-1â¯cells, but siRNA-mediated silencing of CART reduced GLP-1 expression and secretion. Furthermore, acute intravenous administration of CART increased GIP and GLP-1 secretion during an oral glucose-tolerance test in mice. We conclude that CART is a novel constituent of human K- and L-cells with stimulatory actions on incretin secretion and that interfering with the CART system may be a therapeutic avenue for T2D.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
L. Shcherbina, A. Lindqvist, A.-H. Thorén Fischer, E. Ahlqvist, E. Zhang, S.E. Falkmer, E. Renström, J. Koffert, H. Honka, N. Wierup,